Bod Science Ltd
BOD
Company Profile
Business description
Bod Science Ltd is a healthcare company combining the power of nature and science to deliver cannabis-derived health and skincare products, designed to improve lives and transform the medicinal cannabis, CBD, and hemp market. The firm is focused on cannabis drug development and products. The company is focused on progressing Research and Development and a defined clinical trial pathway to commercialize and deliver premium, scientifically trusted products for the consumer and medical markets. It earned it profits and sales revenue from Australia even though have segment in UK, Europe and USA.
Contact
C/- Rodgers Reidy, 210 Clarence Street
Level 12
SydneyNSW2000
AUST: +61 291995018
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs
We plan to raise our fair value estimate of BlackRock stock.
stocks
Our view of ANZ’s strategic plan
Trying to please customers and shareholders with a simpler and leaner bank.
stocks
Perplexing buyback from overvalued ASX share
Earnings continue to grow but investor expectations are too high.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,299.00 | 21.90 | 0.24% |
| CAC 40 | 8,092.08 | 172.46 | 2.18% |
| DAX 40 | 24,214.04 | 22.90 | -0.09% |
| Dow JONES (US) | 46,543.73 | 273.27 | 0.59% |
| FTSE 100 | 9,431.71 | 21.06 | -0.22% |
| HKSE | 25,910.60 | 469.25 | 1.84% |
| NASDAQ | 22,776.56 | 254.86 | 1.13% |
| Nikkei 225 | 47,672.67 | 825.35 | 1.76% |
| NZX 50 Index | 13,307.40 | 30.41 | 0.23% |
| S&P 500 | 6,701.61 | 57.30 | 0.86% |
| S&P/ASX 200 | 8,990.90 | 22.20 | 0.25% |
| SSE Composite Index | 3,912.21 | 46.98 | 1.22% |